← Back to Clinical Trials
Recruiting NCT06361784

NCT06361784 Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06361784
Status Recruiting
Phase
Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Condition Locally Advanced Lung Non-Small Cell Carcinoma
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2024-03-29
Primary Completion 2029-03-29

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2024-03-29 with a primary completion date of 2029-03-29.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The prospective study LOCATION MATTERS aims to investigate the radiation-induced damage to the heart and the cardiovascular system in patients treated with thoracic radiotherapy. Patients enrolled in the study will complete a set of extensive measures at the baseline, end of RT, and 9 months after treatment. Ultrasound exams, CT scans, pulmonary tests and wearable devices will assess functional and morphological parameters and the association with their variation and the dose delivered to the heart substructures and to the normal lung.

Eligibility Criteria

Inclusion Criteria: * Patients with NSCLC * Patients with locally advanced disease (Stage 3) * Patients treated with RT at Fondazione IRCCS Istituto Nazionale dei Tumori Exclusion Criteria: * Previous thoracic radiotherapy * Previous heart surgery

Frequently Asked Questions

Who can join the NCT06361784 clinical trial?

This trial is open to participants of all sexes, studying Locally Advanced Lung Non-Small Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06361784 currently recruiting?

Yes, NCT06361784 is actively recruiting participants. Visit ClinicalTrials.gov or contact Fondazione IRCCS Istituto Nazionale dei Tumori, Milano to inquire about joining.

Where is the NCT06361784 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT06361784 clinical trial?

NCT06361784 is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology